• SANUWAVE cut Q2 2026 revenue guidance to USD 8.5-9.5 million, below the outlook given on the May 13 Q1 earnings call.
• Forecast reduction follows a deterioration in Ultramist capital equipment demand in May and early June, reversing improvement seen in March and April.
• CMS reimbursement clawbacks tied to skin sub and allograft usage drove wound-care practice closures, increasing used Ultramist supply and pressuring new-system sales.
• Applicator consumables remained strong, with the company tracking toward record applicator unit shipments for the quarter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SANUWAVE Health Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160800PRIMZONEFULLFEED9747487) on June 16, 2026, and is solely responsible for the information contained therein.